Triethylene glycol dimethyl ether (TREGDME) dissolving lithium trifluoromethanesulfonate (LiCF3SO3) is studied as a suitable electrolyte medium for lithium battery. Thermal and rheological ...

Merck Manuals launches AI-powered search, offering patients fast, trusted answers from its widely used medical manuals and resources.

Nigerian First Lady, Mrs. Oluremi Tinubu, has emphasised the importance of partnerships in addressing healthcare challenges and empowering communities during her debut appearance at the 7th ...

Merck & Co., Inc. (NYSE:MRK) is one of the best Dow stocks to invest in. On June 9, the company announced that its drug, enlicitide decanoate, achieved its primary goal of lowering a specific type ...

Merck MRK announced FDA approval for its prophylactic long-acting monoclonal antibody, clesrovimab, for the prevention of RSV in newborns and infants born during or entering their first RSV season.

Merck & Co. won US approval for a shot that protects against RSV, the most common cause of hospitalization among infants.

The FDA has blessed Merck’s Enflonsia to prevent RSV in infants. The shot will challenge Sanofi and AstraZeneca’s blockbuster Beyfortus.

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA™ (clesrovimab-cfor) for the prevention ...

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a pair of phase 3 wins for enlicitide decanoate in patients with ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.